Acute Heart Failure From Lyme Carditis

Ryan Koene, MD; David R. Boulware, MD, MPH; Melissa Kemperman, MPH; Suma H. Konety, MD, MS; Morgan Groth, MD; Jose Jessurun, MD; Peter M. Eckman, MD

Carditis can complicate Lyme disease in an estimated <5% of cases, but cardiogenic shock is rare. We report a case of severe biventricular heart failure as a manifestation of a Jarisch-Herxheimer reaction in a patient with early Lyme disease following treatment with ceftriaxone.

Case Report

A 47-year-old woman presented with subacute fever, erythema migrans-like rash, shortness of breath, and spells of dizziness that had progressed to “blackouts.” At admission, complete atrioventricular (AV) block was present (Figure 1A), and ceftriaxone 1g was given initially for suspected Lyme disease. Within 6 hours of antimicrobial treatment, she developed polymorphic ventricular tachycardia (Figure 1B). She was resuscitated with intravenous magnesium, a 150 mg bolus of amiodarone, and defibrillation. Once stabilized, echocardiography revealed severe biventricular heart failure with left ventricular ejection fraction (LVEF) of 10%. Inotrope support was initiated. On hospital day 2, coronary angiography demonstrated patent epicardial coronary arteries, and endomyocardial biopsy revealed diffuse lymphocytic myocarditis (Figure 2). On day 3, methylprednisolone 1000 mg was administered daily for 3 days, followed by a 12-day taper of oral prednisone. An underlying sinus rhythm was present, but third-degree AV block persisted with intermittent 3 to 4 second sinus pauses, requiring placement of a temporary transvenous pacing wire. In a few instances, these had transformed into ventricular tachycardia and ventricular flutter (Figure 1C). Intermittent failure of the temporary pacemaker to sense and capture was evident and became more frequent. These events paralleled the continued rise in serum C-reactive protein (CRP) for the first 3 days of hospitalization (Figure 3), and thus were attributed to diffuse, worsening myocardial inflammation.

Serum enzyme-linked immunosorbent assay and IgM Western blot were positive for Lyme disease, without evidence of coinfection. Repeat echocardiography demonstrated an LVEF of 45%, and hemodynamic support was slowly and successfully withdrawn by day 6. On day 11, oral vasodilators were initiated, and intrinsic conduction had improved sufficiently to permit removal of the temporary pacemaker. Beta-blockers and angiotensin-converting enzyme inhibitors were not initiated because of intermittent bradycardia and acute tubular necrosis. Ceftriaxone was administered for 18 days, followed by oral doxycycline to complete 28 days of therapy. On day 12, cardiac magnetic resonance (MR) demonstrated normal systolic function with an LVEF of 61%. After 2 months, cardiac MR with gadolinium showed preserved systolic function. Neither of the cardiac MR studies revealed gross myocardial edema or fibrosis, suggesting complete recovery.

Discussion

Lyme disease is the most common vector-borne infection in North America, yet cardiac manifestations are relatively uncommon. A United States Center of Disease Control surveillance study of Lyme disease reported cardiac findings of: palpitations (6.6%), conduction abnormalities (1.8%), myocarditis (0.9%), cardiac dysfunction (0.5%), and pericarditis (0.2%).1 From 2001 to 2010, 70 (0.8%) of 9302 confirmed Lyme disease cases reported to the Minnesota Department of Health surveillance system had second- or third-degree AV block. The Infectious Diseases Society of America suggests parenteral ceftriaxone treatment for patients with second- to third-degree AV block.2 Guidelines for steroid administration remain undefined, because reported cases of Lyme carditis have resolved without steroids. However, steroid implementation has been described for cases that exhibited consistent third-degree AV block for a minimum of 24 to 48 hours up to 1 week.3 Meanwhile, acute heart failure in Lyme disease is very rare. The few studies that described severe heart failure were limited to patients having longstanding dilated cardiomyopathy. Among these patients, earlier ceftriaxone treatment may have been associated with complete recovery or improved LVEF, but the role of steroids remains unclear.4

This patient’s clinical course and treatment brought to question what caused her disease; specifically, what is the contribution of foreign bacteria versus the immune response? Her sudden decompensation within hours of antimicrobial therapy, followed by 2 to 3 days of ongoing fevers, increasing CRP, and difficulty with transvenous pacing, all suggested a Jarisch-Herxheimer reaction after initiat-
ing antimicrobial therapy. Antigen release triggered the inflammatory response, the putative pathological entity driving the “disease” state of the patient’s arrhythmias and cardiogenic shock. Corticosteroids temporally were associated with substantial clinical improvement, cessation of life-threatening arrhythmias, marked decline in CRP, and restoration of near-normal LVEF.

**Conclusion**

Severe biventricular failure is a rarely described manifestation of Lyme infection, which in this case was presumably precipitated by a Jarisch-Herxheimer reaction. Implementation of steroids should be considered as adjunctive therapy if CRP acutely rises after initiation of antimicrobial treatment of Lyme carditis. The use of CRP as a diagnostic therapeutic
marker for indicating the role of corticosteroids has not been described and should be investigated further in myocarditis.

**Figure 3.** Treatment time course in relation to serum C-reactive protein: 10% (echo), 45% (echo), and 61% (cardiac magnetic resonance).

**References**


**Disclosures**

Dr Boulware is supported by NIH NIAID K23AI073192.

**KEY WORDS:** myocarditis, heart block, heart failure, Lyme disease, corticosteroids
Acute Heart Failure From Lyme Carditis
Ryan Koene, David R. Boulware, Melissa Kemperman, Suma H. Konety, Morgan Groth, Jose Jessurun and Peter M. Eckman

Circ Heart Fail. 2012;5:e24-e26
doi: 10.1161/CIRCHEARTFAILURE.111.965533
Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/5/2/e24

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Heart Failure can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Heart Failure is online at:
http://circheartfailure.ahajournals.org//subscriptions/